Please use this identifier to cite or link to this item: https://doi.org/10.1158/1535-7163.MCT-13-0187
Title: Off-target effects of c-MET inhibitors on thyroid cancer cells
Authors: Zhou, Y.
Zhao, C.
Gery, S.
Braunstein, G.D.
Okamoto, R.
Alvarez, R.
Miles, S.A.
Doan, N.B.
Said, J.W.
Gu, J.
Phillip Koeffler, H. 
Issue Date: Jan-2013
Citation: Zhou, Y., Zhao, C., Gery, S., Braunstein, G.D., Okamoto, R., Alvarez, R., Miles, S.A., Doan, N.B., Said, J.W., Gu, J., Phillip Koeffler, H. (2013-01). Off-target effects of c-MET inhibitors on thyroid cancer cells. Molecular Cancer Therapeutics 13 (1) : 134-143. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-13-0187
Abstract: Aberrantly activated c-MET signaling occurs in several cancers, promoting the development of c-MET inhibitors. In this study, we found that eight of eight thyroid cancer cell lines (including six anaplastic thyroid cell lines) have prominent expression of c-MET protein. Fifty percent of the thyroid cancer cell lines (four of eight) were growth inhibited by two small molecule c-MET inhibitors (tivantinib and crizotinib) associated with apoptosis and G 2-M cell-cycle arrest. However, crizotinib did not inhibit 50% proliferation of thyroid cancer cells (SW1736 and TL3) at a concentration at which the drug completely inhibited ligand-stimulated c-MET phosphorylation. However, tivantinib was less potent than crizotinib at inhibiting c-MET phosphorylation, but was more potent than crizotinib at decreasing cell growth. Suppressing c-MET protein expression and phosphorylation using siRNA targeting c-MET did not induce cell-cycle arrest and apoptosis. Taken together, tivantinib and crizotinib have off-target(s) activity, contributing to their antitumor activity. In vivo study showed that crizotinib markedly inhibited the growth of thyroid cancer cells (SW1736) in immunodeficient mice. In summary, c-MET inhibitors (tivantinib and crizotinib) suppress the growth of aggressive thyroid cancer cells, and this potential therapeutic benefit results from their non-MET-targeting effects. © 2013 American Association for Cancer Research.
Source Title: Molecular Cancer Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/125424
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-13-0187
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

19
checked on Jun 8, 2021

WEB OF SCIENCETM
Citations

19
checked on Jun 1, 2021

Page view(s)

63
checked on Jun 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.